Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
13.36
+0.09 (0.68%)
Jan 21, 2025, 4:00 PM EST - Market closed
Alvotech Employees
Alvotech had 999 employees as of December 31, 2023. The number of employees increased by 82 or 8.94% compared to the previous year.
Employees
999
Change (1Y)
82
Growth (1Y)
8.94%
Revenue / Employee
$394,313
Profits / Employee
-$441,896
Market Cap
4.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ALVO News
- 4 weeks ago - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - GlobeNewsWire
- 2 months ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 2 months ago - Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors - Business Wire
- 2 months ago - Alvotech (ALVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - GlobeNewsWire
- 2 months ago - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 3 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 3 months ago - European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire